The FDA has accepted the New Drug Application (NDA) for TransCon CNP, a treatment for children with achondroplasia, for priority review. This decision highlights the potential of TransCon CNP in addressing serious complications of achondroplasia and improving health outcomes compared to current therapies. Ascendis Pharmaceuticals aims to collaborate with the FDA to expedite the availability of TransCon CNP, leveraging its innovative TransCon technology platform to develop new therapies with best-in-class potential for unmet medical needs. While the future outcomes may vary, this development signifies a significant step towards advancing treatment options for children with achondroplasia.
Read more from manilatimes.net
